Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints
Category: #health  By Mateen Dalal  Date: 2019-09-09
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints

IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage.

Medtronic plc, one of the world’s biggest medical device companies, has recently announced outcomes from its IN.PACT AV Access clinical trials assessing the PTA (percutaneous transluminal angioplasty) against the IN.PACT™ AV™ DCB (drug-coated balloon) in subjects with non-stented or de novo restenotic AV (arteriovenous) fistulae lesions.

Reportedly, the trials recently achieved its effectiveness endpoints and primary safety, presenting the data at the CIRSE (Cardiovascular and Interventional Radiology Society of Europe) annual meeting in Spain.

Speaking on the move, Andrew Holden, M.D., Associate Professor of Radiology at Auckland University and Director of Interventional Radiology at Auckland Hospital, said that limiting the frequency and maintaining patency of reinterventions demanded AV access sites to properly function remains the major treatment challenges for physicians doctoring AV fistulae lesions.

He said that these results show the potential of IN.PACT AV DCB in addressing these crucial issues and in improving the quality of life of patients going through dialysis.

For the uninitiated, AV fistulae, also known as AV access sites, was developed and used to provide hemodialysis to patients with ESRD (end-stage renal disease). As time passes, vessel restenosis restricts the capability to use AV fistulae efficiently. Hence, in order to rebuild function, patients frequently go through several AV fistula maintenance procedures each year. 

However, the need for repeated reinterventions can lead to a major disruption in serious hemodialysis care and would raise the costs of the healthcare system. Additionally, drug-coated balloons could extend the time between reinterventions by sustaining AV access site patency, increasing the patient’s constant access to dialysis care.

According to sources, the primary effectiveness endpoint reduced CD-TLR (clinically-driven target lesion revascularization). Moreover, additional endpoints involved collective target lesion revascularization, a number of interventions needed to sustain target lesion patency and access circuit primary patency.

Source Credit: http://newsroom.medtronic.com/news-releases/news-release-details/inpact-av-access-trial-meets-primary-safety-and-effectiveness

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...